multiple myeloma	is characterized by	anemia
multiple myeloma	is characterized by	bone lesions
multiple myeloma	is associated with	hypercalcemia
multiple myeloma	is associated with	renal insufficiency
multiple myeloma	is associated with	bone pain
multiple myeloma	causes	fatigue
multiple myeloma	produces	M protein
M protein	is detected by	serum protein electrophoresis
M protein	is detected by	immunofixation
serum protein electrophoresis	detects	monoclonal spike
monoclonal gammopathy	precedes	multiple myeloma
MGUS	increases risk for	multiple myeloma
bone marrow biopsy	shows	clonal plasma cell infiltration
bone lesions	are	lytic
light chains	are elevated in	multiple myeloma
renal impairment	is caused by	light chain nephropathy
immunoglobulin	is overproduced in	multiple myeloma
lenalidomide	is a	immunomodulatory drug
pomalidomide	is a	immunomodulatory drug
bortezomib	is a	proteasome inhibitor
carfilzomib	is a	proteasome inhibitor
dexamethasone	is a	corticosteroid
melphalan	is an	alkylating agent
thalidomide	is an	immunomodulatory drug
autologous stem cell transplant	is a	treatment option
transplant eligibility	depends on	age
high-dose chemotherapy	is used with	stem cell transplant
bortezomib	causes	peripheral neuropathy
lenalidomide	causes	cytopenias
pomalidomide	causes	myelosuppression
dexamethasone	causes	hyperglycemia
combination therapy	improves	response rate
response rate	correlates with	survival
maintenance therapy	reduces	progression
minimal residual disease	predicts	relapse risk
clonal evolution	leads to	drug resistance
bortezomib	is used for	relapsed multiple myeloma
lenalidomide	is used for	relapsed multiple myeloma
carfilzomib	is used for	relapsed multiple myeloma
cytogenetic risk	is associated with	prognosis
del(17p)	is a	high-risk cytogenetic abnormality
t(4;14)	is associated with	poor prognosis
ISS stage	correlates with	survival
Durie-Salmon stage	predicts	prognosis
smoldering myeloma	is a	precursor to multiple myeloma
hypercalcemia	is a	CRAB feature
bone marrow	is the	site of malignant plasma cell infiltration
osteolytic lesions	cause	pathologic fractures
pathologic fractures	complicate	multiple myeloma
infections	are common in	multiple myeloma
neutropenia	occurs with	chemotherapy
anemia	worsens	quality of life
renal impairment	worsens	prognosis
osteoporosis	contributes to	fracture risk
bisphosphonates	prevent	skeletal-related events
denosumab	prevents	skeletal-related events
radiation therapy	palliates	bone pain
daratumumab	is a	monoclonal antibody
daratumumab	targets	CD38
elotuzumab	is a	monoclonal antibody
elotuzumab	targets	SLAMF7
isatuximab	is a	monoclonal antibody
isatuximab	targets	CD38
BCMA	is a target for	CAR-T therapy
CAR-T therapy	yields	response
response	includes	minimal residual disease negativity
minimal residual disease negativity	predicts	longer survival
autologous stem cell transplant	improves	progression-free survival
progression-free survival	correlates with	overall survival
overall survival	is improved by	maintenance therapy
maintenance therapy	reduces	relapse risk
renal function	improves with	treatment
bone density	decreases with	myeloma activity
osteoclasts	are activated by	myeloma cells
kidney involvement	indicates	worse prognosis
serum free light chain assay	is used for	monitoring disease
amyloidosis	occurs with	multiple myeloma
amyloidosis	causes	organ dysfunction
bone lesions	correlate with	prognosis
M protein	indicates	disease activity
IgA myeloma	isotype	of immunoglobulin
non-secretory myeloma	is a	myeloma subtype
light chain myeloma	is a	myeloma subtype
hyperviscosity	is rare in	myeloma
infection risk	increases with	neutropenia
treatment response	requires	serial monitoring
serum M protein	decreases with	effective therapy
bone pain	improves with	analgesia
radiographic response	is used to assess	disease status
bone surveys	show	progression
MRI	reveals	marrow involvement
PET-CT	evaluates	metabolic activity
clonal plasma cells	are reduced by	therapy
drug resistance	leads to	relapse
relapse	requires	salvage therapy
salvage therapy	includes	proteasome inhibitors
bone marrow reserve	limits	transplant eligibility
age	influences	prognosis
death	can result from	progressive disease
